Document is current
Any future updates will be listed below
-
Authors
Nehar-Belaid, Djamel https://orcid.org/0000-0001-6002-5021
Thibodeau, Asa
Eroglu, Alper https://orcid.org/0000-0001-9473-3317
Marches, Radu
Eryilmaz, Giray https://orcid.org/0000-0003-3599-5207
Grabauskas, Titas https://orcid.org/0000-0002-3512-9862
Trinity, Luke https://orcid.org/0000-0002-1578-7964
Unutmaz, Derya
Verschoor, Chris P. https://orcid.org/0000-0001-6190-2655
Gu, Jinghua
Balaji, Uthra
Mejías, Asunción https://orcid.org/0000-0002-5983-8006
Pascual, Virginia https://orcid.org/0000-0002-8806-8426
Kuchel, George A. https://orcid.org/0000-0001-8387-7040
Ramilo, Octavio https://orcid.org/0000-0002-0565-5239
Banchereau, Jacques F.
Ucar, Duygu https://orcid.org/0000-0002-9772-3066
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U01AI165452)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (R01AI142086)
- License Information
-
More Information
Article History
Received: 5 August 2025
Accepted: 19 May 2026
First Online: 15 June 2026
Competing interests
: In the early stage of the study, J.F.B. was a member of the BOD and SAB of Neovacs and Ascend Biopharma, and a SAB member of Cue Biopharma. Now, J.F.B. is the Founder of Immunoledge LLC, an entity designed to advise biotech start-ups. In this role, J.F.B. serves as CIO of Georgiamune, SAB member of Metis Therapeutics, and Adviser to the JAX. O.R. has received research grants from the NIH, Gates Foundation, and Merck; and fees for participation in advisory boards and educational lectures from Merck, Sanofi-Pasteur, Moderna, and Pfizer. The remaining authors declare no competing interests.
